Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United ...

Catalyst Pharmaceuticals Inc. closed $2.35 short of its 52-week high ($24.27), which the company reached on November 8th.

Stephens has recently initiated Catalyst Pharmaceuticals Inc (CPRX) stock to Overweight rating, as announced on November 18, 2024, according to Finviz. Earlier, on March 14, 2024, Citigroup had ...

周三，Oppenheimer重申了对Catalyst Pharmaceutical Partners (NASDAQ:CPRX)股票的"跑赢大盘"评级，目标价保持在29.00美元。这一积极展望是在Catalyst Pharmaceutical宣布与TEVA就Firdapse仿制药营销达成交割协议之后做出的。

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Catalyst Pharmaceuticals (NASDAQ:CPRX) stock jumped 15% Wednesday on news the company had reached an agreement with Teva ...

Catalyst Rises as Q2 Earnings & Revenues Beat Estimates Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) reported adjusted earnings of 56 cents per share for the second quarter of 2024, beating the ...